U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Kiara Fairman
  1. Science & Research (NCTR)

Kiara Fairman M.S., Pharm.D
Leadership Role

Research Biologist — Division of Biochemical Toxicology

Photo of Kiara Fairman


Kiara Fairman, M.S., Pharm.D.
(870) 543-7121

Back to NCTR Principal Investigator page  

About  |  Publications  |  Lab Members


Dr. Kiara Fairman received a bachelor’s degree in chemistry from Alabama State University and a Master of Science in Biological Sciences – Chemistry Track from the University of Texas Southwestern Medical Center at Dallas. She received a Doctor of Pharmacy degree from the University of North Texas System College of Pharmacy in Fort Worth, TX, and holds a Certificate in Regulatory Science from the University of Arkansas Medical Sciences. Dr. Fairman was an Oak Ridge Institute for Science and Education (ORISE) postdoctoral fellow at FDA’s National Center for Toxicological Research (NCTR) from 2019 — 2021 and is currently a staff fellow in the Division of Biochemical Toxicology where she works on physiologically based pharmacokinetic modeling tools for regulatory decision making in pregnancy. Dr. Fairman has attended and presented at multiple conferences and annual meetings in the areas of clinical pharmacology, pharmacy, and chemistry.

In her professional career, Dr. Fairman has received honors and awards such as:

  • Society of Toxicology Biological Modeling Specialty Section — Best Abstract Award (2021)
  • Society of Toxicology Computational Toxicology Specialty Section — Postdoc Award (2021)
  • Society of Toxicology South Central Chapter — 2nd Place Non-Student/Non-Faculty Platform Presentations (2020)
  • American Chemical Society Division of Chemical Toxicology — Outstanding Poster Award 

Research Interests

Dr. Fairman’s research interests are broad and include making physiologically based pharmacokinetic (PBPK) modeling widely available in clinical practice for individualized bedside medicine and using PBPK modeling for unique and underrepresented patient populations such as pregnancy, ethnicity, and disease state modeling. Dr. Fairman also desires to incorporate new advancements such as artificial intelligence (AI) and machine learning into PBPK modeling. Her current research goals are to learn AI and collaborate with AI experts to incorporate AI into a PBPK model for automation and model confidence building as a tool for regulatory use. Her expertise is in PBPK modeling, pharmacy, and chemistry and she is further interested in medicinal chemistry, natural products, and clinical pharmacology research.

Professional Societies/National and International Groups

American Association of Pharmaceutical Scientists
2020 – 2021

American Chemical Society
2019 – 2021

American College of Clinical Pharmacology
2017 – 2021

American Society of Health-System Pharmacists
2016 – 2020

Arkansas Pharmacist Association
2019 – 2021

FDA Fellows Association
Social Media Representative Co-Chair
2019 – 2020

Jefferson Laboratories Fellows Advisory Committee
2019 – 2021

Social Committee Member
2019 – 2020

Kappa Psi Pharmaceutical Fraternity
2016 – 2019

Zeta Lambda Chapter Scholarship Chair & Historian
2016 – 2018

Society of Toxicology (SOT)
2019 – 2021

Postdoctoral Association, SOT
2021 – Present

Risk Assessment Specialty Section, SOT
Postdoctoral Representative
2020 – 2021

Student National Pharmaceutical Association (SNPhA)
2015 – 2019

National Power To End Stroke (PTES), SNPhA
2017 – 2018

University of North Texas Health Science Center Student Society of Health-System Pharmacists
Professional Development Co-chair
2017 – 2018

Selected Publications

Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics: Opportunities and Challenges.
Fairman K., Li M., Ning B., and Lumen A.
Biochem Pharmacol. 2021, 189:114468. doi: 10.1016/j.bcp.2021.114468. [Epub Feb 10, 2021].

Physiologically Based Pharmacokinetic Modeling: A Promising Tool for Translational Research and Regulatory Toxicology.
Fairman K., Li M., Kabadi S., and Lumen A.
Current Opinion in Toxicology. 2020, 23–24, 17-22. https://doi.org/10.1016/j.cotox.2020.03.001. [Epub Dec 31, 2013].

Lab Members

Contact information for all lab members:
(870) 543-7121

Me-Kyoung Choi, Pharm.D.
ORISE Fellow

Pavani Gonnabathula, Ph.D.
ORISE Fellow

Miao Li, Ph.D., Master of Medicine, DABT
Visiting Scientist

Contact Information
Kiara Fairman
(870) 550-3793
Back to Top